Connect Biopharma Holdings Ltd - ESG Rating & Company Profile powered by AI
If you are employed by Connect Biopharma Holdings Ltd and you wish to licence your Sustainability aseessment, please contact us. This page contains a zero-cost Environmental, Social and Governance report covering Connect Biopharma Holdings Ltd. This webpage contains a Q&A table on Connect Biopharma Holdings Ltd.
Connect Biopharma Holdings Ltd in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 4.4; made up of an environmental score of 2.0, social score of 6.4 and governance score of 4.8.
4.4
Medium ImpactEnvironmental
Social
Governance

Peer Group Comparison
Rank | Company | SDG Transparency Score ⓘ | Performance |
---|---|---|---|
1 | Caladrius Biosciences Inc | 8.0 | High |
1 | Can Fite Biopharma Ltd | 8.0 | High |
868 | Trevena Inc | 4.5 | High |
868 | Urogen Pharma Ltd | 4.5 | High |
910 | Connect Biopharma Holdings Ltd | 4.4 | High |
910 | CanBas Co Ltd | 4.4 | High |
910 | CNS Pharmaceuticals Inc | 4.4 | High |
... | ... | ... | |
1970 | Zyden Gentec Ltd | 0.0 | Low |
1970 | iNtRON Biotechnology Inc | 0.0 | Low |
... | ... | ... |

Frequently Asked Questions
Does Connect Biopharma Holdings Ltd have an accelerator or VC vehicle to help deliver innovation?
Does Connect Biopharma Holdings Ltd disclose current and historical energy intensity?
Does Connect Biopharma Holdings Ltd report the average age of the workforce?
Does Connect Biopharma Holdings Ltd reference operational or capital allocation in relation to climate change?
Does Connect Biopharma Holdings Ltd disclose its ethnicity pay gap?
Does Connect Biopharma Holdings Ltd disclose cybersecurity risks?
Does Connect Biopharma Holdings Ltd offer flexible work?
Does Connect Biopharma Holdings Ltd have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Does Connect Biopharma Holdings Ltd disclose the number of employees in R&D functions?
Does Connect Biopharma Holdings Ltd conduct supply chain audits?
Does Connect Biopharma Holdings Ltd disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Is there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Does Connect Biopharma Holdings Ltd conduct 360 degree staff reviews?
Does Connect Biopharma Holdings Ltd disclose the individual responsible for D&I?
Does Connect Biopharma Holdings Ltd disclose current and historical air emissions?
Is there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Is executive remuneration linked to climate performance?
Does the Board describe its role in the oversight of climate-related risks and opportunities?
Does Connect Biopharma Holdings Ltd disclose current and / or historical scope 2 emissions?
Does Connect Biopharma Holdings Ltd disclose water use targets?
Does Connect Biopharma Holdings Ltd have careers partnerships with academic institutions?
Did Connect Biopharma Holdings Ltd have a product recall in the last two years?
Does Connect Biopharma Holdings Ltd disclose incidents of discrimination?
Does Connect Biopharma Holdings Ltd allow for Work Councils/Collective Agreements to be formed?
Has Connect Biopharma Holdings Ltd issued a profit warning in the past 24 months?
Does Connect Biopharma Holdings Ltd disclose parental leave metrics?
Does Connect Biopharma Holdings Ltd disclose climate scenario or pathway analysis?
Does Connect Biopharma Holdings Ltd disclose current and / or historical scope 1 emissions?
Are Operating Expesnses linked to emissions reduction?
Does Connect Biopharma Holdings Ltd disclose the pay ratio of women to men?
Does Connect Biopharma Holdings Ltd support suppliers with sustainability related research and development?
Does Connect Biopharma Holdings Ltd disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Does Connect Biopharma Holdings Ltd reflect climate-related risks in its financial statements?
Is there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Is Connect Biopharma Holdings Ltd involved in embryonic stem cell research?
Does Connect Biopharma Holdings Ltd disclose GHG and Air Emissions intensity?
Does Connect Biopharma Holdings Ltd disclose its waste policy?
Does Connect Biopharma Holdings Ltd report according to TCFD requirements?
Does Connect Biopharma Holdings Ltd disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Does Connect Biopharma Holdings Ltd disclose energy use targets?
Does Connect Biopharma Holdings Ltd disclose its Renewable Energy targets?

Are emissions metrics verified by STBi?

Does Connect Biopharma Holdings Ltd have a policy relating to cyber security?
Have a different question?
Potential Risks for Connect Biopharma Holdings Ltd
These potential risks are based on the size, segment and geographies of the company.
Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, focuses on the discovery and development of immune modulators for the treatment of serious autoimmune diseases and inflammation. The company's lead product candidate is CBP-201, an anti-interleukin-4 receptor alpha antibody, which is in Phase IIb clinical trial for the treatment of inflammatory allergic diseases, such as atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps. Its products also comprise CBP-307, a small molecule modulator of sphingosine 1-phosphate receptor 1, a regulator of T cell mobilization out of lymph nodes into the periphery that is in Phase II for the treatment of autoimmune-related inflammation diseases; CBP-174, a small molecule histamine receptor 3 antagonist for oral administration, which is in a preclinical stage to treat chronic itch associated with skin inflammation; and CBP-233, a preclinical stage humanized antibody against interleukin-33, a cytokine involved in T helper 2 inflammation. The company was founded in 2012 and is headquartered in Taicang, China.